Posted on: 7 March 2023, source: Hemophilia News Today
The European Commission has conditionally approved Hemgenix (etranacogene dezaparvovec), a one-time gene therapy to treat adults with hemophilia B. Hemgenix, originally developed by uniQure, is approved for adults with severe and moderately severe hemophilia B without a history of inhibitors. It’s the first gene therapy for hemophilia B available to patients across all European Union member states, plus Iceland, Liechtenstein, and Norway.